Evidence map›Paper›PMID 30566528›Full record

ArticlePloS one2018

Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.

Valentine U Chukwuma, Nurgun Kose, D Noah Sather, Gopal Sapparapu, Rachel Falk, Hannah King, Vidisha Singh, Rebecca Lampley, Delphine C Malherbe, Noah T Ditto and 8 more

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Innovations in HIV-1 Vaccine Design.Clinical therapeutics · 2020
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Valentine U ChukwumaDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Nurgun KoseVanderbilt Vaccine Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States of America.
D Noah SatherCenter for Infectious Disease Research, Seattle, Washington, United States of America.
Gopal SapparapuVanderbilt Vaccine Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States of America.ORCID 0000-0001-9670-1757
Rachel FalkVanderbilt Vaccine Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States of America.
Hannah KingVanderbilt Vaccine Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States of America.
Vidisha SinghVanderbilt Vaccine Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States of America.
Rebecca LampleyVanderbilt Vaccine Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States of America.
Delphine C MalherbeOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
Noah T DittoCarterra Inc., Salt Lake City, Utah, United States of America.ORCID 0000-0003-4094-3233
Jonathan T SullivanIntegral Molecular, Inc., Philadelphia, Pennsylvania, United States of America.
Trevor BarnesIntegral Molecular, Inc., Philadelphia, Pennsylvania, United States of America.
Benjamin J DoranzIntegral Molecular, Inc., Philadelphia, Pennsylvania, United States of America.
Celia C LabrancheDivision of Surgical Sciences, Duke University, Durham, North Carolina, United States of America.
David C MontefioriDivision of Surgical Sciences, Duke University, Durham, North Carolina, United States of America.
Spyros A KalamsDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Nancy L HaigwoodOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
James E CroweDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.ORCID 0000-0002-0049-1079

Funding

Vaccination design based on natural env genes to elicit broad neutralizing AbsP01AI078064 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI HAIGWOOD, NANCY L · 2009 to 2014
$12.1M
Clonal Analysis of the Human B Cell Response to HIVU01AI078407 · NIAID · VANDERBILT UNIVERSITY · PI CROWE, JAMES E · 2008 to 2012
$3.9M
High-throughput Epitope Mapping of Anti-Viral AntibodiesR43AI096936 · NIAID · INTEGRAL MOLECULAR · PI DORANZ, BENJAMIN J · 2011 to 2011
$242k
NIAID NIH HHS P01 AI078064NIAID NIH HHS R43 AI096936NIAID NIH HHS U01 AI078407
6 · The paper itself

Abstract

Broadly neutralizing antibodies (bNAbs) are rarely elicited by current human immunodeficiency virus type 1 (HIV-1) vaccine designs, but the presence of bNAbs in naturally infected individuals may be associated with high plasma viral loads, suggesting that the magnitude, duration, and diversity of viral exposure may contribute to the development of bNAbs. Here, we report the isolation and characterization of a panel of human monoclonal antibodies (mAbs) from two subjects who developed broadly neutralizing autologous antibody responses during HIV-1 infection. In both subjects, we identified collections of mAbs that exhibited specificity only to a few autologous envelopes (Envs), with some mAbs exhibiting specificity only to a subset of Envs within the quasispecies of a particular sample at one time point. Neutralizing antibodies (NAbs) isolated from these subjects mapped mostly to epitopes in the Env V3 loop region and the CD4 binding site. None of the individual neutralizing mAbs recovered exhibited the cumulative breadth of neutralization present in the serum of the subjects. Surprisingly, however, the activity of polyclonal mixtures comprising individual mAbs that each possessed limited neutralizing activity, could achieve increased breadth of neutralizing activity against autologous isolates. While a single broadly neutralizing antibody targeting one epitope can mediate neutralization breadth, the findings presented here suggest that a cooperative polyclonal process mediated by diverse antibodies with more limited breadth targeting multiple epitopes also can achieve neutralization breadth against HIV-1.

Indexed as

Antibodies, NeutralizingAntibody DiversityB-LymphocytesCells, Culturedenv Gene Products, Human Immunodeficiency VirusEpitope MappingEpitopesHIV-1HIV AntibodiesHIV InfectionsHumansHybridomasNeutralization TestsAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopesHIV Antibodies

Identifiers

PMID30566528
PMCPMC6300260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.